Kun Cheng

Title: Innovations in Prostate Cancer Treatment by Kun Cheng

Introduction

Kun Cheng is an accomplished inventor based in Kansas City, MO (US). He has made significant contributions to the field of cancer research, particularly in the development of targeted therapies for prostate cancer. With a total of 4 patents, Cheng's work focuses on innovative approaches to improve cancer diagnosis and treatment.

Latest Patents

One of Cheng's latest patents involves the discovery of novel prostate-specific membrane antigen (PSMA) targeting peptides. These peptides were identified through a novel combinatorial biopanning method. Among the peptides discovered, GTIQPYPFSWGY (or GTI) exhibits high binding affinity and selectivity to PSMA and PSMA-positive prostate cancer cells. The GTI peptide has been shown to mediate the internalization of the apoptotic KLA peptide into PSMA-positive LNCaP cells, inducing cell death. Furthermore, a FAM-labeled GTI peptide demonstrates high and specific tumor uptake in nude mice bearing human prostate cancer xenografts. This research indicates that the GTI peptide can serve as a PSMA-specific ligand for prostate cancer diagnosis and targeted drug delivery.

Career Highlights

Kun Cheng is affiliated with the University of Missouri, where he conducts his research and development work. His innovative contributions have positioned him as a key figure in the field of cancer therapeutics. Cheng's work not only advances scientific understanding but also holds the potential for significant clinical applications.

Collaborations

Cheng collaborates with notable colleagues, including Wei Jin and Zhijin Chen. Their combined expertise enhances the research efforts and fosters a collaborative environment for innovation.

Conclusion

Kun Cheng's work in developing PSMA-targeting peptides represents a significant advancement in prostate cancer treatment. His innovative research has the potential to improve diagnostic and therapeutic strategies for patients, showcasing the importance of continued innovation in the medical field.